Ara
Toplam kayıt 3, listelenen: 1-3
The Clinical Impact of Low Doses of Dasatinib in Patients with Chronic Myeloid Leukemia
(Akad Doktorlar Yayınevi, 2012)
We report our experience in 41 patients with chronic phase (CF)-chronic myeloid leukemia (CML) who had discontinued imatinib switched to dasatinib, retrospectively. The CF-CML patients received dasatinib at starting dose ...
Effective Molecular Monitoring and the Proper Management of Pleural Effusion During the First-Line Dasatinib Administration in Cml
(Akad Doktorlar Yayınevi, 2012)
Dasatinib is considered an effective treatment agent in imatinib-resistant and newly diagnosed chronic phase CML patients. Patients receiving dasatinib 100 mg once daily regime suffered significantly fewer thrombocytopenia ...